Afsaneh Ighani, MD
Internal Medicine · Dallas, TXNPI 1245335793
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$839
- AbbVie$741
- Amgen$629
- AstraZeneca$612
- Amarin Pharma, Inc.$541
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,097 |
| GSK | 51 | $839 |
| AbbVie(2 entities) | 49 | $741 |
| Amgen | 33 | $629 |
| AstraZeneca(2 entities) | 33 | $612 |
| Amarin Pharma, Inc. | 25 | $541 |
| Lilly USA, LLC | 29 | $443 |
| Boehringer Ingelheim | 23 | $426 |
| Pfizer | 14 | $243 |
| Abbott | 5 | $219 |
| Merck | 10 | $163 |
| Exact Sciences | 6 | $114 |
| Dexcom, Inc. | 6 | $102 |
| VBI Vaccine (delaware) Inc. | 4 | $99 |
| Astellas Pharma US Inc | 5 | $98 |
| Corcept Therapeutics | 4 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| Biohaven Pharmaceuticals, Inc. | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Johnson & Johnson(2 entities) | 3 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Gilead | 4 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Bayer | 2 | $41 |
| Boston Scientific | 1 | $36 |
| Inari Medical, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Recor Medical Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$127
- FARXIGA$116
How this compares
$7,264 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $57,551 |
| JardianceEmpagliflozin | 29 | $38,503 |
| EliquisApixaban | 28 | $29,410 |
| FarxigaDapagliflozin Propanediol | 29 | $20,500 |
| JanuviaSitagliptin Phosphate | 14 | $17,185 |
| InvokanaCanagliflozin | 12 | $11,604 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 11 | $5,771 |
| SynthroidLevothyroxine Sodium | 44 | $4,732 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,715 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,714 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 106 | $3,448 |
| Losartan Potassium | 233 | $2,936 |
| Pantoprazole Sodium | 110 | $2,673 |
| Rosuvastatin Calcium | 182 | $2,607 |
| Levothyroxine Sodium | 262 | $2,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,097 | $57,55141 claims |
| Boehringer IngelheimJardiance | $426 | $38,50329 claims |
| PfizerEliquis | $243 | $29,41028 claims |
| AstraZenecaFarxiga, Symbicort | $612 | $25,21445 claims |
| MerckJanuvia | $163 | $17,18514 claims |
| Johnson & JohnsonInvokana | $70 | $11,60412 claims |
| AbbVieSynthroid | $741 | $4,73244 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $2,195262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.